Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eric Hughes, Teva's EVP of Global R&D & Chief Medical Officer, will present at the BofA Securities Health Care Conference ...
Teva Pharmaceutical Industries (NYSE:TEVA) reported first-quarter 2026 results that management said reflect continued ...
Teva Pharmaceutical Industries (NYSE:TEVA) reported first-quarter 2026 results that management said reflected continued ...
Blackstone committed $400 million to fund development of Teva's promising autoimmune disease drug duvakitug. This deal ...
Teva exceeded all sustainability-linked bond targets, linking financial performance to expanded patient access to medicines and reduced ...
Teva Pharmaceuticals has struck a deal to buy Emalex Biosciences for $700 million | Teva Pharmaceuticals has struck a deal to ...
In the days when that healthcare segment was relatively limited, Teva ruled its niche. But success attracts competition, and ...
The Federal Circuit recently clarified its written description jurisprudence concerning claims directed to methods of using a ...
By Siddhi Mahatole April 29 (Reuters) - Teva Pharmaceutical beat first-quarter profit estimates on Wednesday as growth in its ...
Teva (TEVA) stock jumps as the company exceeds forecasts with Q1 2026 financials. However, it cut its 2026 earnings outlook ...
Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology ...
Pharmaceutical Technology on MSN
Teva signs off $900m Emalex buyout amid strategic pipeline boosting ploy
This deal falls under Teva’s wider strategy to prioritise strategic, financially diligent deals around de-risked, differentiated, late-stage assets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results